Nomir Heading


Bacterial infections represent an $8.0 billion market, which includes 27 million surgical procedures performed each year (i). Surgical procedures are now being blamed for contributing to the increase in incidence and transmission of antibiotic-resistant infections, including methicillin-resistant Staphylococcus aureus (MRSA), commonly referred to as the “Super Bug.” An estimated 292,000 hospitalizations with a diagnosis of S. aureus infection occur annually in U.S. hospitals and, of these, approximately 126,000 hospitalizations are related to MRSA (ii). MRSA is responsible for an average of 94,000 life-threatening infections and 18,650 deaths each year in the United States (iii).

MRSA is a type of bacteria that is resistant to most commonly available antibiotics (iv).  MRSA infections occur most frequently among persons who have weakened immune systems in hospitals and healthcare facilities; however community-associated MRSA infections, such as abscesses, boils, and other pus-filled lesions, are increasingly being diagnosed in healthy people who have not been recently hospitalized or undergone medical procedure (vi) (v).  The most common antibiotic used to treat MRSA infections is vancomycin, but recent evidence suggests resistance to vancomycin is on the rise (vi) (vii) .

MRSA commonly lives harmlessly on the skin and is found in the nose of 20 to 40 percent of healthy individuals (i), but can lead to potentially severe and sometimes deadly infections when exposed to broken skin, particularly in those with compromised immune systems. Increasingly, hospitals have begun to test incoming patients’ noses for MRSA prior to surgery in order to identify and treat infected patients to reduce the risk of transmission.

Nomir has developed an intra-nasal Noveon® device for pre-surgery MRSA eradication. A pilot study of Noveon therapy in the nares (nose) demonstrated that two Noveon treatments, used in combination with erythromycin, eliminated MRSA in six asymptomatic patients. These results support prior in vitro studies, which demonstrated that Noveon exposure kills a number of microbes, including MRSA.

(i) Health Advances Report-July 2008
(ii) Kuehnert MJ et al. Emerging Infectious Diseases 2005; 11: 868-72.
(iii) Klevens, RM et al. Journal of the American Medical Association.2007; 298: 1763-71.
(iv) Centers for Disease Control and Prevention Web site. Healthcare-Associated Methicillin Resistant Staphylococcus aureus (HA-MRSA) Overview. Available at Accessed October 22, 2008.
(v) Centers for Disease Control and Prevention Web site. Community-Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA)Overview. Available at October 22, 2008.
(vi) Sakoulas, G et al. Clinical Infectious Diseases 2006; 42: S40-S50.
(vii) Tenover F, Moellering RC Jr. Clinical Infectious Diseases 2007; 44:1208-15.

top of page